Idarubicin
Information
- Drug Name
- Idarubicin
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| acute myeloid leukemia | DNMT3A R882 DNMT3A R882 | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 22081665 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Idarubicin increases the overall survival and dise... | DNMT3A | DNMT3A R882 DNMT3A R882 | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT04107727 | Active, not recruiting | Phase 2 | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | September 5, 2019 | September 2024 |
| NCT02881086 | Active, not recruiting | Phase 3 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | August 2016 | July 2025 |
| NCT03330821 | Active, not recruiting | Phase 1/Phase 2 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 18, 2018 | October 13, 2025 |
| NCT02688140 | Active, not recruiting | Phase 3 | Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | June 2016 | January 2025 |
| NCT03226418 | Active, not recruiting | Phase 2 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | July 7, 2017 | October 7, 2024 |
| NCT05177731 | Active, not recruiting | Phase 3 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | March 1, 2022 | December 31, 2024 |
| NCT02632708 | Active, not recruiting | Phase 1 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | December 31, 2015 | July 2024 |
| NCT02339740 | Active, not recruiting | Phase 3 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | July 21, 2015 | September 22, 2024 |
| NCT02310321 | Active, not recruiting | Phase 1/Phase 2 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | February 26, 2015 | July 31, 2024 |
| NCT01518556 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia | July 2011 | June 2025 |
| NCT00534469 | Active, not recruiting | Phase 2 | Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | February 8, 2000 | December 30, 2024 |
| NCT00003268 | Completed | Phase 1 | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | January 1998 | December 2003 |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00002565 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | May 25, 1994 | February 5, 2007 |
| NCT00002609 | Completed | Phase 2 | Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission | August 1994 | February 2003 |
| NCT00002719 | Completed | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia | December 1995 | |
| NCT00002798 | Completed | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | August 1996 | |
| NCT00002800 | Completed | Phase 2 | Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome | July 1996 | March 2003 |
| NCT00002812 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia | September 1996 | |
| NCT00002816 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia | December 1996 | April 2006 |
| NCT00002833 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia | October 1994 | April 2002 |
| NCT00002835 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Lymphoma | October 30, 1995 | February 4, 2004 |
| NCT00002868 | Completed | Phase 3 | Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia | November 20, 1997 | |
| NCT00002945 | Completed | Phase 3 | High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | December 1996 | August 2011 |
| NCT00003178 | Completed | Phase 2 | Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia | March 1998 | March 2007 |
| NCT00151255 | Completed | Phase 3 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | June 2004 | January 2011 |
| NCT00198978 | Completed | Phase 4 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | January 2003 | June 2014 |
| NCT00198991 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | April 2003 | June 30, 2013 |
| NCT00199056 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) | October 1999 | December 2005 |
| NCT00199095 | Completed | Phase 4 | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia | February 1997 | June 2003 |
| NCT00331513 | Completed | Phase 1 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | March 2006 | |
| NCT00382954 | Completed | Phase 1 | Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML | February 2004 | October 2008 |
| NCT00413166 | Completed | Phase 2 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | December 2006 | February 2016 |
| NCT00422591 | Completed | Phase 2 | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | December 2006 | January 2017 |
| NCT00458848 | Completed | Phase 2 | Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia | October 2004 | March 2014 |
| NCT00464217 | Completed | Phase 4 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | October 1998 | December 2008 |
| NCT00469859 | Completed | Phase 1/Phase 2 | Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | June 2007 | March 2010 |
| NCT00482833 | Completed | Phase 3 | Phase III Trial in Acute Promyelocytic Leukemia Patients | August 2007 | October 17, 2019 |
| NCT00487448 | Completed | Phase 4 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | July 1998 | June 2007 |
| NCT00505700 | Completed | Phase 1 | VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia | July 2003 | |
| NCT00528398 | Completed | Phase 2 | Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | September 1994 | December 2015 |
| NCT00542971 | Completed | Phase 1/Phase 2 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | October 2007 | May 2011 |
| NCT00620321 | Completed | Phase 2 | A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2008 | January 2010 |
| NCT00656617 | Completed | Phase 2 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | April 2008 | February 2014 |
| NCT00666588 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | April 2008 | December 2012 |
| NCT00831766 | Completed | Phase 1/Phase 2 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | June 25, 2009 | November 16, 2020 |
| NCT00840177 | Completed | Phase 2 | S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia | December 10, 2009 | October 21, 2021 |
| NCT00866918 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | March 9, 2009 | September 30, 2022 |
| NCT00878722 | Completed | Phase 1/Phase 2 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | August 2007 | April 2012 |
| NCT00967057 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | October 2002 | December 2011 |
| NCT01025154 | Completed | Phase 2 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | January 2010 | February 2013 |
| NCT01040559 | Completed | Phase 1 | Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas | December 2009 | June 2012 |
| NCT01132586 | Completed | Phase 1 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | May 2010 | January 2014 |
| NCT01141725 | Completed | Phase 1/Phase 2 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | September 2010 | November 2012 |
| NCT01154439 | Completed | Phase 1 | Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2010 | September 15, 2015 |
| NCT01180322 | Completed | Phase 2 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | November 2010 | October 2, 2016 |
| NCT01289457 | Completed | Phase 1/Phase 2 | Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | February 2, 2011 | June 28, 2017 |
| NCT01435343 | Completed | Phase 1/Phase 2 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | July 2012 | December 2016 |
| NCT01692197 | Completed | Phase 2 | E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes | February 1, 2013 | June 7, 2017 |
| NCT01700413 | Completed | Phase 2 | Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | October 2012 | April 2015 |
| NCT01773408 | Completed | Phase 1 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | February 2013 | June 2016 |
| NCT01779843 | Completed | Phase 1 | Alisertib for Acute Myeloid Leukemia | April 2013 | November 2016 |
| NCT01794702 | Completed | Phase 1/Phase 2 | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | February 20, 2013 | January 11, 2018 |
| NCT01802333 | Completed | Phase 3 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | February 12, 2013 | June 15, 2017 |
| NCT01822015 | Completed | Early Phase 1 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | March 15, 2013 | December 12, 2019 |
| NCT01831232 | Completed | N/A | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | January 2016 |
| NCT01958996 | Completed | Phase 1/Phase 2 | Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma | January 2009 | December 31, 2016 |
| NCT02013648 | Completed | Phase 3 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | July 2014 | February 2024 |
| NCT02046122 | Completed | Phase 1/Phase 2 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | July 2014 | July 31, 2019 |
| NCT02096055 | Completed | Phase 2 | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | April 4, 2014 | November 24, 2020 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT02144675 | Completed | Phase 2 | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | January 2009 | April 26, 2016 |
| NCT02185768 | Completed | Phase 2 | Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II | January 2015 | May 2018 |
| NCT02236013 | Completed | Phase 1 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | January 7, 2015 | July 26, 2021 |
| NCT02249091 | Completed | Phase 2 | A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | September 2014 | July 31, 2018 |
| NCT02283177 | Completed | Phase 2 | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | January 2015 | December 2019 |
| NCT02306291 | Completed | Phase 1/Phase 2 | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | March 2015 | May 2018 |
| NCT02400281 | Completed | Phase 1/Phase 2 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | September 2015 | July 15, 2020 |
| NCT02441803 | Completed | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | September 14, 2015 | September 22, 2021 |
| NCT02464657 | Completed | Phase 1/Phase 2 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | July 2015 | May 7, 2020 |
| NCT02560025 | Completed | Phase 2 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | December 2015 | December 2018 |
| NCT02626338 | Completed | Phase 1/Phase 2 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | February 2016 | February 2018 |
| NCT02652871 | Completed | Phase 1 | LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 9, 2016 | July 16, 2019 |
| NCT02779283 | Completed | Phase 1 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | January 13, 2016 | September 20, 2018 |
| NCT02834390 | Completed | Phase 1 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | August 12, 2016 | October 19, 2017 |
| NCT02835729 | Completed | Phase 1 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2016 | December 27, 2019 |
| NCT02873338 | Completed | Phase 2 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | August 2016 | June 2019 |
| NCT03194932 | Completed | Phase 1 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | July 11, 2017 | June 22, 2022 |
| NCT03661515 | Completed | Phase 1 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | July 17, 2018 | October 15, 2019 |
| NCT04687098 | Completed | Phase 2 | Risk-adapted Therapy for Primary Acute Myeloid Leukemia | February 1, 2012 | November 10, 2022 |
| NCT00003783 | Completed | Phase 2 | Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia | March 1999 | March 2007 |
| NCT00004905 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia | October 1999 | September 2004 |
| NCT00005823 | Completed | Phase 3 | Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | December 1998 | December 2007 |
| NCT00006122 | Completed | Phase 2 | Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | June 2000 | |
| NCT00006232 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma | October 1996 | August 2007 |
| NCT00006367 | Completed | Phase 2 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis | May 2000 | January 2004 |
| NCT00016159 | Completed | Phase 2 | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia | November 2000 | |
| NCT00052299 | Completed | Phase 3 | Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | September 2002 | February 2012 |
| NCT00074737 | Completed | Phase 2 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | April 2004 | May 2007 |
| NCT00077116 | Completed | Phase 2 | Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome | November 2003 | |
| NCT00093483 | Completed | Phase 1 | Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | April 2002 | December 2009 |
| NCT00002517 | Completed | Phase 3 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome | March 1993 | |
| NCT00107523 | Completed | Phase 1 | Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | January 2005 | October 2005 |
| NCT00146120 | Completed | Phase 3 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | May 1998 | May 2005 |
| NCT00151242 | Completed | Phase 2/Phase 3 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2004 | August 2013 |
| NCT06050941 | Not yet recruiting | Phase 2 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | April 2, 2024 | April 2, 2027 |
| NCT03250338 | Recruiting | Phase 3 | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | June 5, 2018 | October 2024 |
| NCT03589729 | Recruiting | Phase 2 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | September 19, 2018 | December 31, 2025 |
| NCT06034470 | Recruiting | Phase 1 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | December 18, 2023 | December 31, 2027 |
| NCT03926624 | Recruiting | Phase 3 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | November 22, 2019 | December 2022 |
| NCT04047641 | Recruiting | Phase 1/Phase 2 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | October 22, 2019 | December 31, 2025 |
| NCT04801797 | Recruiting | Phase 2 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | May 20, 2021 | January 1, 2026 |
| NCT06001788 | Recruiting | Phase 1 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | February 22, 2024 | August 2027 |
| NCT03390387 | Recruiting | N/A | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | November 2015 | November 2025 |
| NCT04375631 | Recruiting | Phase 1 | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | December 3, 2020 | December 31, 2027 |
| NCT00801489 | Recruiting | Phase 2 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | April 4, 2007 | December 30, 2024 |
| NCT03214562 | Recruiting | Phase 1/Phase 2 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | September 26, 2017 | September 30, 2025 |
| NCT02115295 | Recruiting | Phase 2 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | May 19, 2014 | May 31, 2026 |
| NCT05313958 | Recruiting | Phase 2/Phase 3 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | December 1, 2021 | March 30, 2026 |
| NCT02635074 | Terminated | Phase 1 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | November 2016 | November 10, 2017 |
| NCT01607645 | Terminated | Phase 2 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | July 2012 | September 2013 |
| NCT00210366 | Terminated | Phase 2 | Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma | November 2004 | |
| NCT00096148 | Terminated | Phase 2 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2004 | |
| NCT02440568 | Terminated | Phase 1/Phase 2 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | June 5, 2015 | November 30, 2018 |
| NCT00528450 | Terminated | Phase 2 | Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia | September 2007 | January 2011 |
| NCT03860844 | Terminated | Phase 2 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | August 6, 2019 | May 26, 2023 |
| NCT00003729 | Terminated | Phase 2 | Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia | December 1998 | |
| NCT02703272 | Terminated | Phase 3 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | July 1, 2016 | June 11, 2021 |
| NCT02049801 | Terminated | Phase 1 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | December 2014 | November 1, 2017 |
| NCT04778397 | Terminated | Phase 3 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | July 1, 2021 | March 25, 2024 |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT00023920 | Terminated | Phase 2 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | July 2001 | |
| NCT01484171 | Unknown status | Phase 3 | HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | August 2011 | December 2017 |
| NCT00003639 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | November 1993 | |
| NCT02937662 | Unknown status | Phase 2 | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | October 2016 | December 2019 |
| NCT00002771 | Unknown status | Phase 3 | Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | January 1995 | |
| NCT00025402 | Unknown status | Phase 3 | Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia | July 1997 | |
| NCT00002701 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia | October 1995 | |
| NCT01889407 | Unknown status | Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients | August 2013 | July 2016 | |
| NCT00002658 | Unknown status | Phase 3 | Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia | January 1994 | |
| NCT00124813 | Unknown status | Phase 2 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | August 2002 | November 2010 |
| NCT02020161 | Unknown status | Phase 4 | Clinical Guidelines for APL Treatment | June 2012 | December 2021 |
| NCT00180128 | Unknown status | Phase 4 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | January 2000 | November 2012 |
| NCT03553238 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | February 14, 2016 | August 30, 2020 |
| NCT03564704 | Unknown status | Phase 2/Phase 3 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | February 14, 2016 | May 30, 2021 |
| NCT00199147 | Unknown status | Phase 4 | Efficacy of G-CSF-Priming in Elderly AML Patients | January 2000 | |
| NCT00199186 | Unknown status | Phase 2 | Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | March 2002 | |
| NCT00209833 | Unknown status | Phase 2/Phase 3 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | January 1999 | September 2005 |
| NCT00317408 | Unknown status | N/A | Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | April 2004 | |
| NCT00002549 | Unknown status | Phase 3 | Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | November 1993 | |
| NCT00003603 | Unknown status | Phase 3 | Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma | March 1998 | |
| NCT00003602 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | March 1998 | |
| NCT04112589 | Unknown status | Phase 1/Phase 2 | A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | December 26, 2019 | December 2023 |
| NCT02416388 | Unknown status | Phase 2/Phase 3 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | January 2015 | |
| NCT04216771 | Unknown status | Phase 2/Phase 3 | Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | January 2020 | May 2024 |
| NCT00002989 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | March 1997 | |
| NCT05053425 | Unknown status | N/A | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | October 20, 2021 | March 18, 2023 |
| NCT00002532 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia | January 1993 | |
| NCT02848183 | Unknown status | Phase 2 | Optimal Treatment Strategy Based on for Pediatric AML | January 2016 | |
| NCT05404516 | Unknown status | Phase 2 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | January 1, 2020 | December 31, 2023 |
| NCT00002926 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | December 1996 | |
| NCT00003758 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia | December 1998 | |
| NCT00838240 | Unknown status | Phase 1/Phase 2 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia | November 2008 | |
| NCT02527174 | Withdrawn | Phase 1 | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia | November 2016 | September 2018 |
| NCT02905994 | Withdrawn | Phase 1 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | September 2016 | February 2017 |
| NCT00003405 | Withdrawn | Phase 2 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia | April 1998 | April 1999 |
| NCT03444649 | Withdrawn | Phase 1 | Epacadostat, Idarubicin and Cytarabine (EIC) in AML | September 2018 | October 2019 |
| NCT00002761 | Withdrawn | Phase 1/Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia | February 1996 | October 2007 |
| NCT02680951 | Withdrawn | Phase 1 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | December 2015 | December 15, 2017 |
| NCT00004878 | Withdrawn | Phase 2 | Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia |